History

Clomid (clomiphene citrate) is a long-marketed FDA-approved prescription drug dating to the late 1960s (NDA 016131). Its sole approved indication is ovulation induction in women with ovulatory dysfunction who desire pregnancy; it is not FDA-approved for men, and all male use (hypogonadism, fertility preservation) is off-label. Marketed clomiphene citrate is a mixture of roughly 62% enclomiphene, the predominantly anti-estrogenic isomer, and about 38% zuclomiphene, a longer-acting partial estrogen agonist whose half-life can persist beyond a month, so it can accumulate over repeated cycles.

Clomiphene is one of those compounds that constantly gets lumped in with peptides and “research chemicals” in fitness circles, but it is neither. It is a selective estrogen receptor modulator — a small-molecule oral drug in the same chemical family as tamoxifen — and that distinction explains everything about how it works and what it is actually good for. It has a real, FDA-approved medical role in women, a well-studied off-label role in raising testosterone in men, and a recognized list of risks that includes visual disturbances the FDA label warns may be permanent.

What it is

Clomiphene citrate is a nonsteroidal selective estrogen receptor modulator (SERM) of the triphenylethylene class, structurally related to tamoxifen and toremifene. It is taken orally. The marketed drug is not a single molecule but a mixture of two stereoisomers: roughly 62% enclomiphene, the predominantly anti-estrogenic component, and about 38% zuclomiphene, a longer-acting partial estrogen agonist. Zuclomiphene’s long half-life — it can persist for more than a month — means it can accumulate across repeated cycles. (Enclomiphene is the (E)-isomer and zuclomiphene the (Z)-isomer; the older cis/trans labels for these were reversed in the literature after 1976 X-ray crystallography, which is why this profile avoids them.)

Mechanistically, clomiphene competitively occupies estrogen receptors in the hypothalamus and pituitary, blunting estrogen’s negative feedback. The brain effectively “perceives” low estrogen and increases pulsatile GnRH, which raises pituitary LH and FSH. In women this drives follicular development and ovulation. In men, the higher LH and FSH stimulate the testes to make more endogenous testosterone and support spermatogenesis — which is the basis for its off-label use as an alternative to testosterone replacement in men who want to preserve fertility.

The claims

The legitimate, FDA-approved claim is narrow: ovulation induction in women with ovulatory dysfunction who desire pregnancy. Long-term cyclic therapy is not recommended beyond roughly six cycles. Clomiphene is not FDA-approved for men.

The off-label claim in men — secondary (hypogonadotropic) hypogonadism, especially in men who want to preserve fertility — is the reason it draws so much interest. Because exogenous testosterone suppresses the HPG axis and spermatogenesis, clomiphene is positioned as a way to raise a man’s own testosterone without shutting down fertility. (Worth flagging: the NCBI StatPearls chapter loosely states clomiphene is “approved for male spermatogenesis induction.” That conflicts with the actual FDA label, which limits the approved indication to women. The label is authoritative.)

In athletics and bodybuilding, clomiphene is used as an “anti-estrogen” and to attempt to restart endogenous testosterone after anabolic-androgenic steroid use by stimulating LH and FSH, and to counter estrogenic side effects. This profile deliberately includes no doses, cycles, stacks, or post-cycle protocols.

What the evidence actually shows

For raising testosterone in men, the human evidence is reasonably strong and consistent.

Huijben et al. 2022 (Andrology), systematic review and meta-analysis: 19 studies (4 RCTs plus 15 observational), 1,642 patients. Total testosterone rose during clomiphene treatment, with a pooled standardized increase of about 2.60 (95% CI 1.82–3.38). The authors concluded clomiphene effectively raises testosterone but called for more high-quality RCTs.
Hohl et al. 2025 (Archives of Endocrinology and Metabolism), RCT-only meta-analysis of clomiphene/enclomiphene: SERM therapy significantly increased total testosterone versus placebo (mean difference 273.76 ng/dL; 95% CI 191.87–355.66) and showed no significant difference versus testosterone gel (MD 5.41 ng/dL; p=0.83). The evidence was rated moderate quality (wide confidence intervals and heterogeneity) and was underpowered for safety endpoints. Notably, SERMs preserved LH, FSH, and spermatogenesis better than testosterone gel.

The honest bottom line: there is reasonably consistent human evidence that clomiphene raises serum testosterone and, unlike exogenous testosterone, can preserve spermatogenesis. But long-term hard-outcome and safety data remain limited, and male use is not FDA-approved.

Legal and regulatory status

In the United States, clomiphene (Clomid) is a prescription drug, not a controlled substance — legally obtainable only with a valid prescription. Selling or distributing it without authorization, or importing unapproved “research-chemical” SERMs, is illegal. Enclomiphene sold by compounding pharmacies or “research chemical” vendors is not an FDA-approved finished drug.

For comparison among compounds in this PED-support space:

DNP (2,4-dinitrophenol) is not approved for human consumption — it was declared “not fit for human consumption” in the FDA’s early regulatory era and is sold illegally as a “fat burner.”
Mesterolone (Proviron) and fluoxymesterone (Halotestin) are anabolic-androgenic steroids and Schedule III controlled substances under the Controlled Substances Act and Anabolic Steroid Control Act (Halotestin’s label carries the “CIII” designation; both are explicitly enumerated as anabolic steroids).
Insulin and T3 (liothyronine) are prescription drugs, not controlled substances.

In sport, clomiphene (“clomifene”) is prohibited at all times under WADA Section S4 (Hormone and Metabolic Modulators), in the anti-estrogenic SERM subcategory S4.2 — alongside tamoxifen, toremifene, raloxifene, bazedoxifene, ospemifene, cyclofenil, fulvestrant, and elacestrant. Section S4 also covers aromatase inhibitors (anastrozole, letrozole, exemestane, formestane, and others) and other metabolic modulators including insulins and insulin-mimetics, AMPK activators (AICAR, MOTS-c), and PPARδ agonists. New for 2026: BAM15 was added — WADA classifies it under S4.4.1 as an AMPK-activator example, though mechanistically it is a mitochondrial uncoupler that activates AMPK — and a new aromatase-inhibitor example (α-naphthoflavone / 7,8-benzoflavone) was also added. DNP is banned in sport under S4 as a metabolic modulator; the anabolic steroids mesterolone and fluoxymesterone are prohibited at all times under S1. The 2026 list took effect January 1, 2026.

Safety

Clomiphene / SERMs specifically:

Visual disturbances — blurring, spots, flashes, and “scintillating scotomata.” Incidence rises with total dose and duration. The FDA label explicitly warns these may be prolonged and possibly irreversible, especially with increased dose or duration, and can persist after the drug is stopped; they can impair driving or operating machinery.
Venous thromboembolism (VTE): the Clomid label itself lists pulmonary embolism and thrombophlebitis as adverse events and notes that death from thromboembolism can occur in severe ovarian hyperstimulation syndrome. SERMs carry a recognized class risk of thrombosis (DVT/PE), especially in people with clotting risk factors.
Ovarian hyperstimulation syndrome (OHSS) in women — can progress within 24 hours to days; the severe form includes ovarian enlargement, ascites, dyspnea, oliguria, and pleural effusion. Multiple gestation is also a risk.
Other: mood and psychiatric effects, gynecomastia and breast tenderness, hot flashes, and hepatic concerns with prolonged or high exposure. Contraindicated in pregnancy, liver disease, abnormal uterine bleeding, uncontrolled thyroid or adrenal disease, and pituitary tumor.

Other compounds in this space, for honest risk context:

DNP — the most lethal by far. It kills people. It is a mitochondrial uncoupler that causes dose-dependent, uncontrolled hyperthermia (core temperatures up to roughly 44 °C / 111 °F), tachycardia, tachypnea, severe metabolic acidosis, and agitation. There is no antidote; treatment is aggressive supportive cooling and fluids only. It has a high fatality rate with numerous documented deaths in dieters and bodybuilders, and the margin between a “fat-loss” amount and a fatal amount is dangerously narrow.
Insulin (non-diabetic/PED use): risk of severe, potentially fatal hypoglycemia — seizures, coma, brain injury, death — which can occur unpredictably and require emergency glucose.
Aromatase inhibitors: over-suppression of estrogen causes adverse lipids, accelerated bone loss / osteoporosis risk, joint pain, and low libido or mood effects.
T3 (liothyronine): exogenous thyroid hormone can cause cardiac arrhythmias, tachycardia, atrial fibrillation, and bone loss, and can suppress the endogenous thyroid axis (rebound hypothyroidism on cessation).

None of this is medical advice.

Bottom line

Clomiphene is a SERM, not a peptide and not a steroid. It is FDA-approved only for ovulation induction in women; all male use is off-label. The human evidence that it raises testosterone in hypogonadal men is reasonably strong and consistent — and, unlike exogenous testosterone, it tends to preserve LH, FSH, and spermatogenesis — though long-term safety data are limited and the trials are underpowered for safety. It is a prescription drug in the US, not a controlled substance, but unapproved “research-chemical” SERMs sit outside the regulated system. In sport it is banned at all times. And it carries real risks, including visual disturbances the FDA label warns can be permanent and a recognized thromboembolic risk.

Evidence grade: Strong human. Strong human evidence that it raises testosterone in hypogonadal men while preserving fertility; not FDA-approved for men, and long-term safety data remain limited.

Clomiphene (Clomid)